"We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-specific NK cell engager and IPH4502, our innovative ADC targeting ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data ...

ADC是肿瘤领域发展最快的治疗方式之一，目前已有15种ADC获批，超过210种正在进行临床试验。近年来，ADC的药物研发进入百花齐放阶段，特别是在HER2、EGFR、Trop2、CLDN18.2、Nectin-4等靶点上展示出显著的疗效和良好的安全性 ...

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific ...

Nectin-4 is a cell-adhesion molecule overexpressed in several tumor types, including breast, ovarian, lung, colorectal, pancreatic and urothelial cancer. Enfortumab vedotin (EV), an anti-Nectin-4 ...

研究人员首次证明，一种特殊设计的“迷你蛋白质”可以直接向肿瘤细胞传递辐射剂量，肿瘤细胞表面表达一种叫做Nectin-4的蛋白质，这种蛋白质在许多不同的癌症中都有发现。上周五，在西班牙巴塞罗那举行的第36届EORTC-NCI-AACR分子靶点和癌症治疗研讨会上 ...

Researchers have shown for the first time that it is possible for a specially-designed ‘mini-protein’ to deliver a radiation ...

Researchers have shown for the first time that it is possible for a specially designed 'mini-protein' to deliver a radiation ...